Conference Track

Resistance and Management of Treatment-Experienced Patients

Source: CCO Independent Conference Coverage of the 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Possible Source of Infection of "NYC Rapid Progressor" Identified
Screening for Acute Primary HIV Infection in High-Risk, Resource-Poor Setting
Government Antiretroviral Treatment Program in Chile Lowers Mortality
Ritonavir-Boosted Atazanavir Maintenance Therapy Sustains Virologic Suppression in Plasma, But Lower Rates of Suppression in Semen, CSF
GS 934: Impact of Baseline Resistance on Outcomes, and Resistance Patterns Among Patients With Virologic Failure
TEDDI Trial: High Rate of Virologic Failure With Tenofovir/Didanosine/Efavirenz Initial Therapy
Continued Lamivudine Monotherapy After Treatment Failure Associated With Fewer Immunologic and Clinical Failures Than Full Treatment Interruption
No Improvement in Virologic Outcomes for Children Who Received Genotypic Resistance Testing
Tenofovir Plus Emtricitabine Superior to Fixed-Dose Zidovudine/Lamivudine, Each With Efavirenz, in Antiretroviral Therapy-Naive Patients
Concomitant Enfuvirtide Increases Efficacy of Tipranavir/Ritonavir in Patients With Extensive Treatment Experience
Short-Term Disease Progression Rates Appear Similar in Patients Newly Diagnosed With Drug-Resistant or Drug-Susceptible HIV-1
Absence of Primary PI Resistance Mutations Following Virologic Failure in Patients Receiving First-Line Saquinavir-Ritonavir-Based Regimen

Expert Analysis

Resistance and Management of Treatment-Experienced Patients

CME Program Director: John P. Phair, MD

Faculty:

Daniel R. Kuritzkes, MD
Kathleen E. Squires, MD
Andrew R. Zolopa, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Explain the potential risks and benefits of treatment simplification and interruption in treatment-experienced patients.
Recount data on the efficacy of approved and investigational antiretrovirals in multiclass-experienced patients.
Describe strategies to reduce the frequency of drug resistance associated with prophylactic use of antiretrovirals in pregnancy.
Describe HAART regimens associated with increased risk of treatment failure.
Discuss data on the impact of baseline resistance mutations on treatment outcomes in patients initiating HAART.

CREDIT INFORMATION

Release Date: 09/22/05

Expiration Date: 09/21/06

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.6 Nursing contact hours

Pharmacists: 1.4 contact hours (0.14 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.